Bulletin

WHO

WHO works to strengthen mental health services in Libya in the aftermath of Storm Daniel

October 10, 2023

WHO

Five key themes for improved mental health care for refugees and migrants

October 10, 2023

Roche

Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies

October 10, 2023

WHO

Egypt becomes the first country to achieve WHO validation on the path to elimination of hepatitis C

October 9, 2023

WHO

WHO-OHCHR launch new guidance to improve laws addressing human rights abuses in mental health care

October 9, 2023

WHO

WISH summit calls for sustainable mega sports event legacies which boost physical activity

October 6, 2023

Roche

Majority of newborn babies with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi able to sit independently after 1 year of treatment

October 4, 2023

WHO

101 health workers killed in Libya in the aftermath of Storm Daniel

October 2, 2023

Roche

Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD

October 2, 2023

WHO

Joint statement of the United State of America and the World Health Organization on the U.S - WHO strategic Dialogue

September 27, 2023

WHO

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease

September 7, 2023

Roche

Roche’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes

August 29, 2023

WHO

WHO initiative signs new licensing agreements on COVID-19 technologies

August 29, 2023

< 1 … 35 36 37 38 39 40 41 42 43 … 94 >

Bulletin

WHO works to strengthen mental health services in Libya in the aftermath of Storm Daniel

Five key themes for improved mental health care for refugees and migrants

Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies

Egypt becomes the first country to achieve WHO validation on the path to elimination of hepatitis C

WHO-OHCHR launch new guidance to improve laws addressing human rights abuses in mental health care

WISH summit calls for sustainable mega sports event legacies which boost physical activity

Majority of newborn babies with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi able to sit independently after 1 year of treatment

101 health workers killed in Libya in the aftermath of Storm Daniel

Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD

Joint statement of the United State of America and the World Health Organization on the U.S - WHO strategic Dialogue

Global stakeholders agree to a new charter on patient safety rights

Unprecedented focus on global public health at UN General Assembly

WHO launches new resources on prevention and decriminalization of suicide

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease

Roche’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes

WHO initiative signs new licensing agreements on COVID-19 technologies

Company

Resources